The reiteration of an Overweight rating and the maintenance of a $107 price target by a reputable analyst like Kristen Kluska from Cantor Fitzgerald could signal a strong vote of confidence in Ultragenyx Pharmaceutical's stock. This endorsement may positively influence investor sentiment and potentially drive the stock price up in the short term.